tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
KalVista Pharmaceuticals: EKTERLY Launch and Financial Update
PremiumCompany AnnouncementsKalVista Pharmaceuticals: EKTERLY Launch and Financial Update
2M ago
KalVista Pharmaceuticals: Buy Rating Affirmed Amidst Promising Ekterly Launch and Strong Financial Position
Premium
Ratings
KalVista Pharmaceuticals: Buy Rating Affirmed Amidst Promising Ekterly Launch and Strong Financial Position
2M ago
Buy Rating for KalVista Pharmaceuticals Amid Ekterly’s Market Launch and Insurance Challenges
Premium
Ratings
Buy Rating for KalVista Pharmaceuticals Amid Ekterly’s Market Launch and Insurance Challenges
2M ago
Buy Rating for KalVista Pharmaceuticals Driven by FDA Approval and Strategic Market Entry of Ekterly
PremiumRatingsBuy Rating for KalVista Pharmaceuticals Driven by FDA Approval and Strategic Market Entry of Ekterly
2M ago
KalVista price target raised to $40 from $32 at Jefferies
Premium
The Fly
KalVista price target raised to $40 from $32 at Jefferies
2M ago
Musk to launch new political party, Trump threatens BRICS tariff: Morning Buzz
Premium
The Fly
Musk to launch new political party, Trump threatens BRICS tariff: Morning Buzz
2M ago
Optimistic Buy Rating for KalVista Pharmaceuticals Amidst Positive FDA Interactions and Imminent Decision on Sebetralstat
PremiumRatingsOptimistic Buy Rating for KalVista Pharmaceuticals Amidst Positive FDA Interactions and Imminent Decision on Sebetralstat
2M ago
Stifel calls report of Makary pushing for KalVista CRL ‘highly surprising’
Premium
The Fly
Stifel calls report of Makary pushing for KalVista CRL ‘highly surprising’
2M ago
KalVista selloff on Endpoints report unwarranted, says JonesResearch
Premium
The Fly
KalVista selloff on Endpoints report unwarranted, says JonesResearch
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100